NANEXA Share Price Performance
SEK 1.73
-0.73 (-29.67%)
33.1% overvalued intrinsic discount
SEK 1.30
Fair Value
Price SEK 1.73
daemningen4500 SEK 1.30
Fair ValueSEK 1.30
Share Pricen/a
Nanexa AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
NANEXA Community Narratives
DA
Fair Value SEK 1.3 33.1% overvalued intrinsic discount
19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?
Nanexa AB is a Swedish pharmaceutical company that specializes in drug delivery systems. Here's a brief overview of its corporate history, ownership, focus, and potential: Corporate History Nanexa was founded in 2007 and is headquartered in Uppsala, Sweden.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
DA
SEK 1.3
33.1% overvalued intrinsic discount
daemningen4500 Fair Value
Revenue
28.21% p.a.
Profit Margin
14.37%
Future PE
27.83x
Price in 2030
SEK 1.72
Trending Discussion
Recently Updated Narratives
DA
19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?
Fair Value: SEK 1.3 33.1% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nanexa AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 19, 2026
- -0.25
- 50.23%
- -122.35%
- 27.6%
About NANEXA
- Founded
- 2007
- Employees
- 15
- CEO
- WebsiteView website
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a depot drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk and AstraZeneca for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
